cis-decahydronaphthalene-4a-methanol | 99992-19-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: cis-decahydronaphthalene-4a-methanol
• 英文别名: 4a(2H)-Naphthalenemethanol, octahydro-；2,3,4,5,6,7,8,8a-octahydro-1H-naphthalen-4a-ylmethanol
• CAS: 99992-19-5
• 化学式: C₁₁H₂₀O
• 分子量: 168.279
• InChiKey: ZVYRRWLYOCFIMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  cis-decahydronaphthalene-4a-methanol 在 三氧化硫吡啶 、 三乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 0.75h， 生成 cis-decahydronaphthalene-4a-carbaldehyde
  参考文献：
  名称：

  Regio- and stereoselective acylation of saturated carbocycles via Norrish–Yang photocyclization

  摘要：

  A regio- and stereoselective acylation of saturated carbocycles has been achieved through two-step reactions involving the Norrish-Yang photocyclization of 1,2-diketones and subsequent ring opening of the alpha-hydroxy-cyclobutanones. The C-H activation of the carbocycle proceeds regioselectively at vicinal to the diketone moiety resulting in stereoselective formation of cis-fused bicycles. The following C-C cleavage affords vicinally cis-acylated carbocycles. Predictability, generality, and practicality of the present strategy have been demonstrated using variously modified saturated carbocycles. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.12.027
• 作为产物：
  描述：

  cis/trans-decahydronaphthalene-4a-carboxylic acid 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 生成 cis-decahydronaphthalene-4a-methanol
  参考文献：
  名称：

  Regio- and stereoselective acylation of saturated carbocycles via Norrish–Yang photocyclization

  摘要：

  A regio- and stereoselective acylation of saturated carbocycles has been achieved through two-step reactions involving the Norrish-Yang photocyclization of 1,2-diketones and subsequent ring opening of the alpha-hydroxy-cyclobutanones. The C-H activation of the carbocycle proceeds regioselectively at vicinal to the diketone moiety resulting in stereoselective formation of cis-fused bicycles. The following C-C cleavage affords vicinally cis-acylated carbocycles. Predictability, generality, and practicality of the present strategy have been demonstrated using variously modified saturated carbocycles. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.12.027

文献信息

• [EN] SUBSTITUTED UREA DERIVATIVES AND USES THEREOF IN MEDICINE<br/>[FR] DÉRIVÉS D'URÉE SUBSTITUÉS ET LEUR UTILISATION EN MÉDECINE
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2015043492A1

  公开（公告）日：2015-04-02

  Provided herein are substituted urea derivatives or stereoisomers, geometric isomers, tautomers, N-oxides, hydrates, solvates, metabolites, esters, pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions thereof, which are useful in modulating the FLT3 kinase activity, inhibiting FLT3-ITD, and treating the diseases mediated by FLT3 kinase or caused by FLT3-ITD.

  本文提供了替代尿素衍生物或其立体异构体、几何异构体、互变异构体、N-氧化物、水合物、溶剂合物、代谢物、酯类、药学上可接受的盐或其前药，以及用于调节FLT3激酶活性、抑制FLT3-ITD并治疗由FLT3激酶介导或由FLT3-ITD引起的疾病的药物组合物。
• [EN] SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF<br/>[FR] DÉRIVÉS D'URÉE SUBSTITUÉS ET UTILISATIONS PHARMACEUTIQUES DE CEUX-CI
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2016008433A1

  公开（公告）日：2016-01-21

  Provided herein are novel substituted urea derivatives, and pharmaceutical compositions thereof. Also provided herein are uses of the compounds or pharmaceutical compositions thereof for preventing, managing, treating or lessening a proliferative disease, andmodulating the activity of protein kinase.

  本文提供了新颖的取代脲衍生物及其药物组合物。本文还提供了这些化合物或药物组合物用于预防、管理、治疗或减轻增殖性疾病，并调节蛋白激酶活性的用途。
• ACYLATING AGENTS, ACYLATION METHOD WITH THE USE OF THE SAME AND ADAMANTANE DERIVATIVES
  申请人：Daicel Chemical Industries, Ltd.

  公开号：EP0990634A1

  公开（公告）日：2000-04-05

  An acylating agent of the invention includes (A) a 1,2-dicarbonyl compound or its hydroxy reductant, (B) oxygen, and (C) at least one compound selected from (c1) a metallic compound and (C2) N-hydroxyphthalimide or another imide compound. As the 1,2-dicarbonyl compound or its hydroxy reductant (A), biacetyl, 2,3-butanediol or the like can be used. As the metallic compound (c1), cobalt acetate, or another cobalt compound, for example, can be employed. By reacting an adamantane derivative or another compound having a methine carbon atom with the acylating agent, an acyl group can be introduced to the methine carbon atom with efficiency.

  本发明的酰化剂包括(A)1,2-二羰基化合物或其羟基还原剂，(B)氧和(C)至少一种选自(c1)金属化合物和(C2)N-羟基邻苯二甲酰亚胺或另一种酰亚胺化合物的化合物。作为 1,2-二羰基化合物或其羟基还原剂 (A)，可以使用生物乙酰基、2,3-丁二醇或类似物。作为金属化合物（c1），可以使用醋酸钴或其他钴化合物等。将金刚烷衍生物或其他具有甲烷碳原子的化合物与酰化剂反应，可以有效地将酰基引入甲烷碳原子。
• SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF
  申请人：Sunshine Lake Pharma Co., Ltd.

  公开号：EP3169671A1

  公开（公告）日：2017-05-24
• US6429314B1
  申请人：——

  公开号：US6429314B1

  公开（公告）日：2002-08-06